SCNN1A

Epithelial sodium channel subunit alpha · P37088 · SCNN1A on Sugi Atlas →

5,603 patent compounds predicted against SCNN1A, 1,945 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
552-02 Free Base (SCHEMBL2015164)	1.00	20/20
SCHEMBL916348	0.94	20/20
SCHEMBL5671579	0.86	20/20
Hydrochloric Acid (SCHEMBL937636)	0.79	20/20
Hydrochloric Acid (SCHEMBL1961465)	0.79	20/20
SCHEMBL916744	0.76	20/20
SCHEMBL938374	0.75	20/20
SCHEMBL1996614	0.75	20/20
SCHEMBL9913760	0.74	20/20
SCHEMBL937541	0.74	20/20
Hydrochloric Acid (SCHEMBL915539)	0.73	20/20
SCHEMBL9913775	0.72	20/20
Hydrochloric Acid (SCHEMBL4660231)	0.72	20/20
SCHEMBL9913770	0.71	20/20
Hydrochloric Acid (SCHEMBL936974)	0.70	20/20
SCHEMBL1134593	0.70	20/20
SCHEMBL9913782	0.68	20/20
SCHEMBL708474	0.67	20/20
SCHEMBL10028707	0.67	20/20
SCHEMBL10028706	0.66	20/20

Clinical trials — most relevant to SCNN1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety	PHASE3	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome	PHASE1/PHASE2	RECRUITING
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Double Blind Crossover Comparison of Diuretics in the Young	nan	UNKNOWN
Adverse Airway Effects From Tobacco and E-Cigarettes	nan	UNKNOWN
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age	nan	RECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis	nan	UNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a SCNN1A binder may also engage these)

Protein	Name	Similarity
H2Q5A1	—	1.000	H2Q5A1 →
P55270	—	1.000	P55270 →
O97741	—	1.000	O97741 →
P37089	—	0.998	P37089 →
Q61180	—	0.995	Q61180 →
Q9R1N2	—	0.991	Q9R1N2 →
Q92075	—	0.970	Q92075 →
Q9JHS6	—	0.967	Q9JHS6 →
Q7TNS7	—	0.961	Q7TNS7 →
Q96FT7	—	0.961	Q96FT7 →
K7GET2	—	0.960	K7GET2 →
Q708S5	—	0.950	Q708S5 →
Q62962	—	0.948	Q62962 →
Q96MU8	—	0.948	Q96MU8 →
A2AIR5	—	0.946	A2AIR5 →
A2RRU4	—	0.946	A2RRU4 →
Q9P0L9	—	0.945	Q9P0L9 →
C0HL12	—	0.944	C0HL12 →
O75077	—	0.944	O75077 →
MCOLN1	Mucolipin-1	0.944	landscape →
A6QM06	—	0.944	A6QM06 →
P97260	—	0.943	P97260 →
Q925H0	—	0.943	Q925H0 →
O46547	—	0.942	O46547 →
Q9R1M7	—	0.942	Q9R1M7 →
GRIN3A	Glutamate receptor ionotropic, NMDA 3A	0.942	landscape →
Q924S4	—	0.942	Q924S4 →
Q5MNU5	—	0.942	Q5MNU5 →
Q7TSQ1	—	0.941	Q7TSQ1 →
Q99N43	—	0.941	Q99N43 →